Last updated on January 2014

A randomized placebo-controlled study to determine the safety, tolerability, pharmacodynamics and clinical efficacy of ILV-094 (an IL-22 antibody) administered intravenously to subjects with atopic dermatitis (AD)


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Eczema (Atopic Dermatitis)
  • Age: Between 18 - 75 Years
  • Gender: Male or Female

  • Moderate to Serve AD
  • No known malignancy or history of malignancy
  • No history of HIV, Hepatitis B or C

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.